129 related articles for article (PubMed ID: 33734640)
1. Soluble forms of immune checkpoints in ovarian cancer.
Kovaleva OV; Belova TP; Kushlinsky DN; Korotkova EA; Podlesnaya PA; Gratchev AN; Zinoviev SV; Tereshkina IV; Sokolov NY; Kudlay DA; Kushlinskii NE
Klin Lab Diagn; 2021 Mar; 66(2):80-86. PubMed ID: 33734640
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of Soluble Forms of the Immune Checkpoint Components PD-1/PD-L1/B7-H3, CD314/ULBP1, and HLA-G in Peripheral Blood of Melanoma Patients Receiving Blockers of Programmed Cell Death Protein PD-1.
Gershtein ES; Mochalova AS; Korotkova EA; Samoilova EV; Vashketova OI; Kuz'min YB; Sokolov NY; Kushlinskii NE
Bull Exp Biol Med; 2023 Aug; 175(4):481-486. PubMed ID: 37773572
[TBL] [Abstract][Full Text] [Related]
3. Soluble B7-H3 in Ovarian Cancer and Its Predictive Value.
Kovaleva OV; Belova TP; Korotkova EA; Kushlinskii DN; Gratchev AN; Petrikova NA; Kudlay DA; Kushlinskii NE
Bull Exp Biol Med; 2021 Aug; 171(4):472-474. PubMed ID: 34542756
[TBL] [Abstract][Full Text] [Related]
4. [The content of the soluble forms PD-1 and PD-L1 in blood serum of patients with gastric cancer and their relationship with clinical and morphological characteristics of the disease.].
Gershtein ES; Ognerubov NA; Chang VL; Delektorskaya VV; Korotkova EA; Sokolov NY; Polikarpova SB; Stilidi IS; Kushlinskii NE
Klin Lab Diagn; 2020; 65(6):347-352. PubMed ID: 32459892
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of the levels of soluble forms of receptor and ligand of the immunity control point PD-1/PD-L1 in the blood serum of patients with typical bone osteosarcoma and chondrosarcoma.
Kushlinskii NE; Alferov AA; Boulytcheva IV; Timofeev YS; Korotkova EA; Khvan OT; Kuzmin YB; Kuznetsov IN; Bondarev AV; Shchupak MY; Sokolov NY; Efimova MM; Gershtein ES; Sushentsov EA; Aliev MD; Musaev ER
Klin Lab Diagn; 2020 Dec; 65(11):669-675. PubMed ID: 33301655
[TBL] [Abstract][Full Text] [Related]
6. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
[TBL] [Abstract][Full Text] [Related]
7. Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of
Koukourakis MI; Kontomanolis E; Sotiropoulou M; Mitrakas A; Dafa E; Pouliliou S; Sivridis E; Giatromanolaki A
Anticancer Res; 2018 Oct; 38(10):5739-5745. PubMed ID: 30275195
[TBL] [Abstract][Full Text] [Related]
8. [Novel miRNAs as Potential Regulators of PD-1/PD-L1 Immune Checkpoint, and Prognostic Value of MIR9-1 and MIR124-2 Methylation in Ovarian Cancer].
Kushlinskii NE; Loginov VI; Utkin DO; Filippova EA; Burdennyy AM; Korotkova EA; Pronina IV; Lukina SS; Smirnova AV; Gershtein ES; Braga EA
Mol Biol (Mosk); 2020; 54(6):990-996. PubMed ID: 33276362
[TBL] [Abstract][Full Text] [Related]
9. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
[TBL] [Abstract][Full Text] [Related]
10. Soluble Ligand of the Immune Checkpoint Receptor (sPD-L1) in Blood Serum of Patients with Renal Cell Carcinoma.
Kushlinskii NE; Gershtein ES; Morozov AA; Goryacheva IO; Filipenko ML; Alferov AA; Bezhanova SD; Bazaev VV; Kazantseva IA
Bull Exp Biol Med; 2019 Jan; 166(3):353-357. PubMed ID: 30627905
[TBL] [Abstract][Full Text] [Related]
11. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus].
Luo L; Shu M; Li S; Cai Y
Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624
[TBL] [Abstract][Full Text] [Related]
12. [Soluble programmed death-1 and soluble programmed death ligand 1 protein expression and immune status in patients with recurrent aphthous ulcer].
Nan J; Liang L; Li L; Xiaoqin S; Xing J; Yang C
Hua Xi Kou Qiang Yi Xue Za Zhi; 2017 Jun; 35(3):286-290. PubMed ID: 28675014
[TBL] [Abstract][Full Text] [Related]
13. Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer.
Chatterjee J; Dai W; Aziz NHA; Teo PY; Wahba J; Phelps DL; Maine CJ; Whilding LM; Dina R; Trevisan G; Flower KJ; George AJT; Ghaem-Maghami S
Clin Cancer Res; 2017 Jul; 23(13):3453-3460. PubMed ID: 27986748
[No Abstract] [Full Text] [Related]
14. Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma.
Buderath P; Mairinger F; Mairinger E; Böhm K; Mach P; Schmid KW; Kimmig R; Kasimir-Bauer S; Bankfalvi A; Westerwick D; Hager T
Int J Gynecol Cancer; 2019 Nov; 29(9):1389-1395. PubMed ID: 31492714
[TBL] [Abstract][Full Text] [Related]
15. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
16. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
17. Elevated Soluble PD-L1 in Pregnant Women's Serum Suppresses the Immune Reaction.
Okuyama M; Mezawa H; Kawai T; Urashima M
Front Immunol; 2019; 10():86. PubMed ID: 30833943
[No Abstract] [Full Text] [Related]
18. Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.
Zhang X; Liu L; Zhou S; Zhao K; Song Z; Hu G; Zhang T; Li Y; Qiu L; Li L; Qian Z; Meng B; Pan Y; Ren X; Wang X; Zhang H; Fu K
Hematol Oncol; 2019 Aug; 37(3):270-276. PubMed ID: 31074879
[TBL] [Abstract][Full Text] [Related]
19. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
20. [The meaning of PD-1/PD-L1 pathway in ovarian cancer pathogenesis].
Piętak P; Pietrzyk N; Pawłowska A; Suszczyk D; Bednarek W; Kotarski J; Wertel I
Wiad Lek; 2018; 71(5):1089-1094. PubMed ID: 30176647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]